Full results & analysis
Available in the Gosset platform where reported.
01
Overview
Phase 4, randomised trial of entecavir and tenofovir in Cirrhosis, sponsored by Asian Institute of Medical Sciences. Primary endpoint: Safety and efficacy at 48 weeks. Status: unknown.
02
Design
- Study design
- Randomized
03
Who it enrols
Patients aged 18-70 with chronic HBV infection, decompensated cirrhosis (CTP > 7), and HBV DNA > 10^3 copies/mL.
04
Endpoints
Primary
Safety and efficacy
Beyond the preview
Go deeper on NCT02238860.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02238860.